- Home
- ANEB vs CELU Comparison
ANEB vs CELU Comparison
Compare ANEB & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- CELU
- Stock Information
- Founded
- ANEB 2020
- CELU 2016
- Country
- ANEB United States
- CELU United States
- Employees
- ANEB N/A
- CELU N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- CELU Health Care
- Exchange
- ANEB Nasdaq
- CELU Nasdaq
- Market Cap
- ANEB 39.0M
- CELU 42.2M
- IPO Year
- ANEB 2021
- CELU N/A
- Fundamental
- Price
- ANEB $2.85
- CELU $3.12
- Analyst Decision
- ANEB Buy
- CELU
- Analyst Count
- ANEB 2
- CELU 0
- Target Price
- ANEB $8.00
- CELU N/A
- AVG Volume (30 Days)
- ANEB 1.1M
- CELU 589.8K
- Earning Date
- ANEB 09-24-2025
- CELU 05-08-2025
- Dividend Yield
- ANEB N/A
- CELU N/A
- EPS Growth
- ANEB N/A
- CELU N/A
- EPS
- ANEB N/A
- CELU N/A
- Revenue
- ANEB N/A
- CELU $54,220,000.00
- Revenue This Year
- ANEB N/A
- CELU $23.29
- Revenue Next Year
- ANEB N/A
- CELU N/A
- P/E Ratio
- ANEB N/A
- CELU N/A
- Revenue Growth
- ANEB N/A
- CELU 138.11
- 52 Week Low
- ANEB $0.80
- CELU $1.00
- 52 Week High
- ANEB $3.42
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- ANEB 66.43
- CELU 58.55
- Support Level
- ANEB $1.53
- CELU $2.95
- Resistance Level
- ANEB $3.42
- CELU $3.50
- Average True Range (ATR)
- ANEB 0.20
- CELU 0.43
- MACD
- ANEB 0.05
- CELU 0.02
- Stochastic Oscillator
- ANEB 69.84
- CELU 47.44
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.